Cartesian Therapeutics (NASDAQ: RNAC) director gets new stock awards

Rhea-AI Filing Summary

Cartesian Therapeutics director Patrick Zenner reported new equity awards. On January 2, 2026, he acquired 2,600 shares of common stock at a price of $0, representing restricted stock units that will vest in full on January 2, 2027. On the same date, he was granted a stock option for 7,800 shares of common stock at an exercise price of $6.76 per share, first exercisable on January 2, 2027 and expiring on January 1, 2036. After these transactions, he directly beneficially owned 12,974 shares of common stock and 7,800 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZENNER PATRICK J

(Last) (First) (Middle)

C/O CARTESIAN THERAPEUTICS, INC.

7495 NEW HORIZON WAY

(Street)

FREDERICK MD 21703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cartesian Therapeutics, Inc. [ RNAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		2,600	A(1)	$0	12,974	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.76	01/02/2026		A		7,800		01/02/2027	01/01/2036	Common Stock	7,800	$0	7,800	D

Explanation of Responses:

1. Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

Remarks:

	/s/ Matthew Bartholomae, Attorney-in-Fact for Patrick Zenner	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Cartesian Therapeutics (RNAC) report for Patrick Zenner?

The filing shows director Patrick Zenner received two equity awards on January 2, 2026: 2,600 shares of common stock via restricted stock units and a stock option for 7,800 shares of common stock.

How many Cartesian Therapeutics (RNAC) shares does Patrick Zenner own after this Form 4?

After the reported transactions, Patrick Zenner directly beneficially owned 12,974 shares of common stock and held 7,800 stock options.

What are the key terms of Patrick Zenner’s stock option grant at Cartesian Therapeutics (RNAC)?

The stock option covers 7,800 shares of common stock at an exercise price of $6.76 per share, is first exercisable on January 2, 2027, and expires on January 1, 2036.

When do Patrick Zenner’s restricted stock units in Cartesian Therapeutics (RNAC) vest?

Each restricted stock unit represents a right to receive one share of common stock and will vest in full on January 2, 2027.

Is the reported Cartesian Therapeutics (RNAC) insider transaction a purchase or a grant?

The events reported are grants, coded as "A" (acquired) for both the 2,600 restricted stock units and the 7,800-share stock option, both at a price of $0 for the awards themselves.

What is Patrick Zenner’s role at Cartesian Therapeutics (RNAC) according to the filing?

The filing identifies Patrick Zenner as a director of Cartesian Therapeutics, Inc. and not a 10% owner or officer.